S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: A multicenter phase II study

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 5, 2008, Pages 849-855

  Furuse, Junji ^a   Okusaka, Takuji ^b   Boku, Narikazu ^c   Ohkawa, Shinichi ^d   Sawaki, Akira ^e   Masumoto, Toshikazu ^f   Funakoshi, Akihiro ^g  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Biliary tract cancer; Chemotherapy; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; DOXORUBICIN; GEMCITABINE; IRINOTECAN; TEGAFUR; URACIL;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY TRACT CANCER; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEMALE; GALLBLADDER; HUMAN; LEUKOPENIA; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LOCALIZATION; VATER PAPILLA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; DRUG COMBINATIONS; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; OXONIC ACID; SURVIVAL ANALYSIS; TEGAFUR;

EID: 49749136654     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0673-7     Document Type: Article

References (32)

1. T Andre C Tournigand O Rosmorduc S Provent F Maindrault-Goebel D Avenin 2004 Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study Ann Oncol 15 9 1339 1343
2. DC Doval JS Sekhon SK Gupta J Fuloria VK Shukla S Gupta 2004 A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer Br J Cancer 90 8 1516 1520
3. G Falkson JM MacIntyre CG Moertel 1984 Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer Cancer 54 6 965 969
4. J Furuse T Okusaka A Funakoshi N Boku K Yamao S Ohkawa 2005 A phase II study of S-1 in patients with metastatic pancreatic cancer Proc Am Soc Clin Oncol 23 16s (Abstract No: 4104)
5. J Furuse T Okusaka A Funakoshi K Yamao M Nagase H Ishii 2006 Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer Jpn J Clin Oncol 36 9 552 556
6. JO Gallardo B Rubio M Fodor L Orlandi M Yanez C Gamargo 2001 A phase II study of gemcitabine in gallbladder carcinoma Ann Oncol 12 10 1403 1406
7. B Glimelius K Hoffman PO Sjoden G Jacobsson H Sellstrom LK Enander 1996 Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 6 593 600
8. Haskell CM (ed) (2001) Cancer treatment, 5th edn. WB Saunders Co, Philadelphia
9. M Hejna M Pruckmayer M Raderer 1998 The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature Eur J Cancer 34 7 977 986
10. M Ikeda T Okusaka H Ueno C Morizane J Furuse H Ishii 2005 A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma Jpn J Clin Oncol 35 8 439 443
11. M Kawahara K Furuse Y Segawa K Yoshimori K Matsui S Kudoh 2001 Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br J Cancer 85 7 939 943
12. TW Kim HM Chang HJ Kang JR Lee MH Ryu JH Ahn 2003 Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer Ann Oncol 14 7 1115 1120
13. JJ Knox D Hedley A Oza R Feld LL Siu E Chen 2005 Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial J Clin Oncol 23 10 2332 2338
14. JJ Knox D Hedley A Oza LL Siu GR Pond MJ Moore 2004 Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience Ann Oncol 15 5 770 774
15. Koyama Y (ed) (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28:101-130
16. B Levin 1999 Gallbladder carcinoma Ann Oncol 10 Suppl 4 129 130
17. MH Lin JS Chen HH Chen WC Su 2003 A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas Chemotherapy 49 3 154 158
18. Makuuchi M (ed) (2000) The general rules for the clinical and pathological study of primary liver cancer November 2000, 4th edn. Kanehara, Tokyo
19. S Mani D Sciortino B Samuels R Arrietta RL Schilsky EE Vokes 1999 Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma Invest New Drugs 17 1 97 101
20. Nagakawa T (ed) (2003) General rules for surgical and pathological studies on cancer of the biliary tract September 2003, 5th edn. Kanehara, Tokyo
21. Nomura K (ed) (2005) Cancer statistics in Japan 2005. Foundation for Promotion of Cancer Research (FPCR), Tokyo
22. A Ohtsu H Baba Y Sakata Y Mitachi N Horikoshi K Sugimachi 2000 Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group Br J Cancer 83 2 141 145
23. T Okusaka H Ishii A Funakoshi K Yamao S Ohkawa S Saito 2006 Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer Cancer Chemother Pharmacol 57 5 647 653
24. YZ Patt MM Hassan A Aguayo AK Nooka RD Lozano SA Curley 2004 Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma Cancer 101 3 578 586
25. YZ Patt DV Jones Jr A Hoque R Lozano A Markowitz I Raijman 1996 Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer J Clin Oncol 14 8 2311 2315
26. T Saeki S Takashima M Sano N Horikoshi S Miura S Shimizu 2004 A phase II study of S-1 in patients with metastatic breast cancer-a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group Breast Cancer 11 2 194 202
27. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 11 1715 1720
28. T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 5 548 557
29. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216
30. Ueno H, Furuse J, Yamao K, Funakoshi A, Boku N, Ohkawa S et al (2007) A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. ASCO 2007 Gastrointestinal Cancers Symposium (Abstract No: 148)
31. H Ueno T Okusaka M Ikeda Y Takezako C Morizane 2004 Phase II study of S-1 in patients with advanced biliary tract cancer Br J Cancer 91 10 1769 1774
32. AB van Kuilenburg RA De Abreu AH van Gennip 2003 Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency Ann Clin Biochem 40 Pt 1 41 45